WO2004050098A1 - 安定化されたアンスラサイクリン系化合物の凍結乾燥製剤 - Google Patents
安定化されたアンスラサイクリン系化合物の凍結乾燥製剤 Download PDFInfo
- Publication number
- WO2004050098A1 WO2004050098A1 PCT/JP2003/015196 JP0315196W WO2004050098A1 WO 2004050098 A1 WO2004050098 A1 WO 2004050098A1 JP 0315196 W JP0315196 W JP 0315196W WO 2004050098 A1 WO2004050098 A1 WO 2004050098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- amrubicin
- freeze
- preparation
- cysteine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Definitions
- the present invention provides a method for stabilizing amrubicin or a salt thereof, which is useful as a cancer chemotherapeutic agent.
- amrubicin 1-dihydroxy-1,5,12-naphthacenedione
- amrubicin 1-dihydroxy-1,5,12-naphthacenedione
- Anthracycline compounds such as amrubicin are unstable in solution.
- a method of filling the powder or freeze-drying to obtain a dissolution type injection at the time of use is generally performed.
- decomposed products tended to increase during the production and storage of amrubicin preparations. From the viewpoint of quality assurance of pharmaceutical products, it is extremely important to suppress the increase of these decomposed products as much as possible over a long period of time, and it has been desired to develop a method for further stabilizing an amrubicin preparation.
- anthracycline anticancer drugs that have been clinically applied in addition to amnolevicin. As shown below, commercially available anthracycline anticancer drugs other than amrubicin have a hydroxyl group at the 9-position of anthracycline, but amrubicin has a structural difference from an amino group at the 9-position .
- the stable pH of amrubicin hydrochloride is biased toward the acidic side, and the stable pH range is narrow.
- the stability of the active ingredient is different, when developing a method for stabilizing an amrubicin preparation, it is necessary to examine conditions unique to amrubicin, which are different from other anthracycline anticancer drugs.
- L-cysteine or Or a method of adding a salt thereof is known. This method could suppress the production of deamino acid (3), but could increase the production of desaccharide (2) depending on the conditions.
- the water content in the freeze-dried amrubicin product greatly affects the production of deglycosidase (2). If the water content is controlled within a certain range, the production of desaccharides (2) is suppressed and stored for a long time. Sometimes a stable freeze-dried product can be obtained.
- the temperature of the process in the solution state affects the formation of degraded products (mainly deamino form (3)), and by performing the process at a sufficiently low temperature
- the present invention is as follows.
- (1) contains L-cystine or a salt thereof
- the water content in the preparation is 0 to about 4% by weight based on the weight of the lyophilized powder.
- L-cysteine or its salt is (1) L-cysteine in the range of about 5 to about 2 Omg, or (2) an equivalent amount of L-cysteine salt, based on 10 mg of amrubicin hydrochloride.
- the stabilized preparation according to any one of items [1] to [8], wherein
- Amrubicin salt was found to have a diffraction angle (2 ⁇ ) of powder X-ray diffraction pattern: 6.3 soil 0.3, 10.1 ⁇ 0.3, 20.3 ⁇ 0.3, 26.5 ⁇ 0 3.
- the stabilized preparation according to any one of items [1] to [: 11], which is crystalline amrubicin hydrochloride exhibiting a main peak at 30.9 ⁇ 0.3 degrees.
- Items [1] to [12] are prepared by preparing an aqueous solution containing (a) amrubicin or a salt thereof, and (b) L-cysteine or a salt thereof, aseptically filtering the aqueous solution, and freeze-drying the aqueous solution. ] The method for producing the stabilized preparation according to any one of [1] to [10].
- steps (1) to (3) are performed at about 15 ° C. or lower [14] to
- steps (1) to (3) are performed at about 10 ° C or lower [14:] to
- the salt of amrubicin was found to have a diffraction angle (2 ⁇ ) of the powder X-ray diffraction diagram (2 ⁇ ) 6.3 Sat 0.3, 10.1 ⁇ 0.3, 20.3 ⁇ 0.3, 26.5 ⁇ 0.3 Item 14.
- the production method according to any one of Items [14] to [20], wherein the method is crystalline amrubicin hydrochloride showing a main peak at 26.9 ⁇ 0.3 degrees.
- a method for producing a stable freeze-dried preparation of amrubicin comprising the following steps (1) to (4):
- Amrubicin hydrochloride L-cysteine (or equivalent amount of L-cysteine salt) in the range of about 5 to about 20 mg per 10 mg of amrubicin hydrochloride
- the aqueous solution obtained in (3) is freeze-dried to obtain a freeze-dried preparation in which the water content of the preparation is 0 to about 4% by weight based on the weight of the freeze-dried powder.
- a cancer chemotherapeutic agent comprising a freeze-dried preparation produced by the production method according to any one of [13 :) to [23].
- Figure 1 shows a dehydrated product (2) of a freeze-dried amrubicin formulation containing various amounts of water when subjected to a stability test at 40 ° C (Experimental Examples 2 and 3). ) Is generated.
- the horizontal axis represents elapsed time / month.
- Each polygonal line represents the data of the following products, respectively.
- water in the preparation means% by weight based on the weight of the lyophilized powder, unless otherwise specified.
- the content of the deglycosylated (2) and deaminated (3) represents the weight% based on amrubicin.
- the water content in the formulation is from 0 to about 4% by weight, preferably from 0 to about 3.5% by weight, more preferably from about 0.5 to about 3.5% by weight, even more preferably from about 0.5 to about 2.0%. Weight percent is effective.
- Acids that can be used for the salt of amrubicin include hydrobromic acid, citric acid, tartaric acid, lactic acid, fumaric acid, maleic acid, methanesulfonic acid and the like, in addition to hydrochloric acid.
- hydrochloric acid In the case of amrubicin, the more stable crystalline form, j3-type crystalline amrubicin hydrochloride (diffraction angle (2 ⁇ ) in powder X-ray diffraction pattern: 6.3 ⁇ 0.3, 10.1 ⁇ 0.3, It is more preferable to use crystalline amrubicin hydrochloride showing main peaks at 20.3 ⁇ 0.3, 26.5 ⁇ 0.3 and 26.9 ⁇ 0.3 degrees (Japanese Patent No. 2975018). ,.
- the powder X-ray diffraction pattern can be measured by using an X-ray diffractometer RINT250 of Rigaku Electric Co., Ltd. using 1.541A of Cu ⁇ ⁇ .
- L-cystine As a salt of L-cystine, a hydrochloride is usually used, and as other salts, a sulfate and the like can be mentioned.
- L-cysteine or a salt thereof may be a solvate such as a hydrate thereof.
- preferred is L-cysteine hydrochloride monohydrate.
- the amount of L-cysteine or its salt to be added is not particularly limited. Due to the relationship between the stability of amrubicin and the pharmacological activity of the additive, for example, the amount of amrubicin hydrochloride to 10 Omg (titer) About 0.5 to about 250 mg, preferably about 3 to about 80 mg, more preferably about 3 to about 45 mg is suitable. It is particularly preferable to add L-cystine salt in the range of about 5 to about 20 mg or an equivalent amount of L-cysteine salt to an amrubicin hydrochloride 10 Omg titer.
- “the equivalent amount of L-cysteine salt” means that the amount of L-cysteine contained is equimolar.
- the "equivalent amount" of L-cysteine hydrochloride is 157.6 mg for 121.2 mg L-cysteine, and the "equivalent amount” of L-cysteine hydrochloride monohydrate is 175.6 mg.
- L-cysteine hydrochloride monohydrate is used as the L-cysteine salt, the amount equivalent to L-cystine J in the range of about 5 to about 2 Omg is defined as L-cystine hydrochloride monohydrate. about 7.2- about 29 mg.
- pH was around it Nozomu preferred, more preferably a pH of about 2.0 to about 3.5, which is adjusted to between P H about 2 to about 5 Considering the characteristics of amrubicin, More preferably, the pH is in the range of about 2.2 to about 3.0, and particularly preferably, the pH is in the range of about 2.4 to about 3.0.
- a base and / or an acid may be added.
- the base that can be used as the pH adjuster in the present invention includes, for example, hydroxides of alkali metal (eg, sodium, potassium, etc.) and alkaline earth metals (eg, magnesium, calcium, etc.). ) And alkali metal salts of weak acids.
- alkali metal salt of a weak acid include carbonate, hydrogen carbonate, phosphate, hydrogen phosphate, dihydrogen phosphate, citrate, hydrogen citrate, and dihydrogen citrate. . These may be hydrates, and any two or more of them may be used as a mixture.
- the base that can be used as the pH regulator include, for example, sodium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, sodium carbonate, potassium hydrogen carbonate, sodium hydrogen phosphate, and phosphoric acid.
- Examples include potassium hydrogen, sodium phosphate, sodium citrate, sodium dihydrogen citrate, calcium hydroxide, hydrates thereof, and mixtures thereof.
- Preferred examples of the base include sodium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate and the like. More preferably, sodium hydroxide or a hydroxide hydration rim is used.
- examples of the acid that can be used as a pH adjuster include hydrochloric acid, sulfuric acid, and the like.
- additives such as an excipient which can be added as a usual preparation component may be added.
- the excipient include lactose, sucrose, palatinose, glucose, maltose, fructose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, and mixtures thereof.
- Preferred excipients include lactose, sucrose, sucrose, maltose, fructose, mannitol, xylitol, inositol, dextran, and mixtures thereof. More preferably, lactose, mannitol and mixtures thereof are mentioned.
- the lyophilized preparation is prepared by, for example, dissolving amrubicin or a salt thereof, L-cysteine or a salt thereof, and an excipient as necessary in distilled water for injection, and adding a small amount of a base and
- the aseptically filtered solution is filled into a vial, freeze-dried to form a powdered formulation, and the injection is stored in this state and dissolved in water at the time of use Used for administration.
- the steps from dissolution to immediately before freeze-drying are preferably performed at about 15 ° C or lower, more preferably at about 10 ° C or lower.
- the stabilized lyophilized preparation containing amrubicin or a salt thereof of the present invention can be used as a cancer chemotherapeutic agent for treating various cancer diseases.
- the cancer to be treated is not particularly limited, and includes cancer diseases including hematologic cancer and solid cancer.
- the dosage when used in the treatment of human Bok for intravenous administration, for example, body surface area of the human m 2 Ah or daily dose 5 to 3 0 0 mg, preferably 2 0 to 2 5 O mg, more preferably Can be treated by continuous infusion in the range of 35 to 16 Omg.
- the administration schedule includes, for example, a single administration, an administration once a day and a daily administration for three days.
- the water content of the freeze-dried preparation varies depending on conditions such as the degree of vacuum, temperature and drying time during freeze-drying, but the water content can be controlled by adjusting these as shown in Experimental Examples and Examples.
- Example 1 The water content of the freeze-dried preparation varies depending on conditions such as the degree of vacuum, temperature and drying time during freeze-drying, but the water content can be controlled by adjusting these as shown in Experimental Examples and Examples.
- Amrubicin hydrochloride 20 mg titer L-cysteine hydrochloride monohydrate 3.2 mg Lactose (lactose) 50mg is added as a excipient and dissolved in distilled water for injection so that the concentration of amrubicin hydrochloride becomes 5mgZml, finely adjusted to a pH of about 3 with a trace amount of sodium hydroxide and hydrochloric acid, and sterile filtered. 10 ml were filled into 18 ml vials. Put this in a freeze dryer and after freezing sufficiently, sublimate the water at 20 ° C for 49 hours to prevent the freeze-dried cake from melting while controlling the temperature and degree of vacuum, and then dry the rubber stopper and cap. A stable freeze-dried preparation was obtained by sealing (water content: 0.9%).
- Amrubicin hydrochloride 20mg titer L-cysteine hydrochloride monohydrate 3.2mg and lactose (lactose) 50mg as excipients are dissolved in distilled water for injection, and trace amounts of sodium hydroxide and hydrochloric acid are added.
- the mixture was finely adjusted to pH about 3 with sterile filtration, and filled in an 18-ml vial. Put this in a freeze dryer, after freezing sufficiently, sublimate and dry the water for 7 hours while controlling the temperature and vacuum to prevent the freeze-dried cake from melting, then put a rubber stopper and seal the cap. As a result, a freeze-dried preparation A was obtained.
- Amrubicin hydrochloride (20 mg), L-cysteine hydrochloride monohydrate (3.2 mg), and ratatose (lactose) (50 mg) as an excipient were dissolved in distilled water for injection, and trace amounts of sodium hydroxide and hydrochloric acid were added. in perform sterile filtration is finely adjusted to P H of about 3 was filled into 18ml volume vial. Put this in a freeze dryer, freeze it sufficiently, sublimate the water so that the freeze-dried cake does not melt while controlling the temperature and degree of vacuum, and then dry it thoroughly. A freeze-dried preparation was obtained by sealing the rubber stopper with a cap (water content: 1.3%, desaccharide (2); 0.63%, deamino (3); 0.12%).
- the obtained lyophilized product was conditioned (added moisture) to a water content of about 3.5% (water-added preparation A) and about 5% (water-added preparation B) at 40 ° C.
- Table 2 shows the results of storage stability tests for 3 months and 6 months, and the measurement of moisture (measured by the Karl Fischer method) and degradation products (measured by the HPLC method).
- Example 3 The freeze-dried preparations obtained in Examples 2 and 3 were subjected to a storage stability test at 40 ° C for 3 months and 6 months, and moisture (measured by the Karl Fischer method) and decomposed products (measured by the HPLC method) Table 3 shows the results of the measurements. Table 3
- the amount of deglycoside (2) produced during long-term storage depends on the water content at the start of the stability test, and the water content in the formulation should be within the range of 0 to about 4% by weight.
- the freeze-dried preparation controlled at a low concentration has a markedly improved stability compared to a preparation with a high water content, and in particular, suppresses the production of deglycosidase (2), indicating that the freeze-dried preparation is stable enough for long-term storage. confirmed. Although there was no significant difference in the amount of the deamino product (3), the tendency was found to increase slightly when the water content was low.
- the deamino derivative (3) is present in an amount of about 1% or more, it may cause turbidity when preparing an injectable solution from the lyophilized amrubicin preparation. Therefore, its production must be suppressed to a very small amount.
- the amount of the deamino form (3) increases little by little. Therefore, it is very important to control the amount of solution produced during the formulation process.
- the preparation process in the state (for example, steps (1) to (3) in the above item [13]) be performed at about 15 ° C or lower, more preferably at about 10 ° C or lower. .
- amrubicin unlike other anthracycline anticancer drugs, unlike amrubicin, it does not have an amino group at the 9-position of anthracycline, so there is no need to consider the formation of the deamino derivative, and only the deglycoside in the formulation process. Should be considered.
- the above manufacturing conditions have made it possible to mass produce freeze-dried amrubicin.
- the long-term storage of amrubicin which is useful as a cancer chemotherapeutic agent,
- a sufficiently stable freeze-dried preparation can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2509449A CA2509449C (en) | 2002-11-29 | 2003-11-27 | Lyophilized preparation of stabilized anthracycline compounds |
KR1020057009501A KR101059715B1 (ko) | 2002-11-29 | 2003-11-27 | 안정화된 안트라사이클린계 화합물의 동결 건조 제제 |
US10/536,397 US8445653B2 (en) | 2002-11-29 | 2003-11-27 | Freeze-dried preparation of stabilized anthracycline compound |
JP2004556847A JP4594736B2 (ja) | 2002-11-29 | 2003-11-27 | 安定化されたアンスラサイクリン系化合物の凍結乾燥製剤 |
AU2003284478A AU2003284478A1 (en) | 2002-11-29 | 2003-11-27 | Freeze-dried preparation of stabilized anthracycline compound |
EP03775944A EP1570849A4 (en) | 2002-11-29 | 2003-11-27 | FREEZE-DRIED PREPARATION OF STABILIZED ANTHRAZYCLIN COMPOUND |
US12/885,333 US20110021452A1 (en) | 2002-11-29 | 2010-09-17 | Lyophilized preparation of stabilized anthracycline compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002348500 | 2002-11-29 | ||
JP2002-348500 | 2002-11-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/885,333 Continuation US20110021452A1 (en) | 2002-11-29 | 2010-09-17 | Lyophilized preparation of stabilized anthracycline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004050098A1 true WO2004050098A1 (ja) | 2004-06-17 |
Family
ID=32462917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015196 WO2004050098A1 (ja) | 2002-11-29 | 2003-11-27 | 安定化されたアンスラサイクリン系化合物の凍結乾燥製剤 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8445653B2 (ja) |
EP (1) | EP1570849A4 (ja) |
JP (1) | JP4594736B2 (ja) |
KR (1) | KR101059715B1 (ja) |
CN (2) | CN101926780B (ja) |
AU (1) | AU2003284478A1 (ja) |
CA (1) | CA2509449C (ja) |
TW (1) | TW200507859A (ja) |
WO (1) | WO2004050098A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513519A (ja) * | 2005-05-11 | 2008-05-01 | シコール インコーポレイティド | 安定した凍結乾燥されたアントラサイクリングリコシド |
JP2009501708A (ja) * | 2005-07-14 | 2009-01-22 | インデナ・ソチエタ・ペル・アチオニ | チョウセンアザミ抽出物、その使用及びそれを含む配合物 |
WO2010137131A1 (ja) | 2009-05-27 | 2010-12-02 | 大日本住友製薬株式会社 | アンスラサイクリン系化合物の安定な凍結乾燥製剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102423303B (zh) * | 2011-11-21 | 2017-04-12 | 山东新时代药业有限公司 | 一种盐酸替罗非班注射用冻干粉针剂 |
CN104798262B (zh) | 2012-10-19 | 2017-07-07 | 李尔公司 | 电连接器组件 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302729A1 (en) * | 1987-08-05 | 1989-02-08 | Sumitomo Pharmaceuticals Company, Limited | Stabilised anthracycline preparation |
WO1999028331A2 (en) * | 1997-11-28 | 1999-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | Crystalline amrubicin hydrochloride |
WO2003035660A1 (fr) * | 2001-10-23 | 2003-05-01 | Sumitomo Chemical Company, Limited | Stabilisation d'hydrochlorure d'amrubicine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5976099A (ja) | 1982-10-22 | 1984-04-28 | Sumitomo Chem Co Ltd | アミノナフタセン誘導体とその製造方法 |
CA1187182A (en) * | 1983-04-29 | 1985-05-14 | Patrick Van Gheluwe | Method for determining the optimum component ratios in a polyurethane foam process |
JPS6075473A (ja) | 1983-09-30 | 1985-04-27 | Sumitomo Chem Co Ltd | アミノナフタセン誘導体 |
JP2975018B2 (ja) * | 1997-11-28 | 1999-11-10 | 住友製薬株式会社 | 結晶性塩酸アムルビシン |
JP4374404B2 (ja) * | 2001-10-23 | 2009-12-02 | 大日本住友製薬株式会社 | 塩酸アムルビシンの安定化方法 |
JP4374403B2 (ja) * | 2001-10-23 | 2009-12-02 | 大日本住友製薬株式会社 | 塩酸アムルビシンの保存方法 |
-
2003
- 2003-11-27 KR KR1020057009501A patent/KR101059715B1/ko not_active IP Right Cessation
- 2003-11-27 CA CA2509449A patent/CA2509449C/en not_active Expired - Fee Related
- 2003-11-27 EP EP03775944A patent/EP1570849A4/en not_active Withdrawn
- 2003-11-27 US US10/536,397 patent/US8445653B2/en not_active Expired - Fee Related
- 2003-11-27 AU AU2003284478A patent/AU2003284478A1/en not_active Abandoned
- 2003-11-27 CN CN2010102729107A patent/CN101926780B/zh not_active Expired - Fee Related
- 2003-11-27 CN CNA200380109192XA patent/CN1741804A/zh active Pending
- 2003-11-27 WO PCT/JP2003/015196 patent/WO2004050098A1/ja active Application Filing
- 2003-11-27 JP JP2004556847A patent/JP4594736B2/ja not_active Expired - Lifetime
- 2003-11-28 TW TW092133582A patent/TW200507859A/zh not_active IP Right Cessation
-
2010
- 2010-09-17 US US12/885,333 patent/US20110021452A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302729A1 (en) * | 1987-08-05 | 1989-02-08 | Sumitomo Pharmaceuticals Company, Limited | Stabilised anthracycline preparation |
WO1999028331A2 (en) * | 1997-11-28 | 1999-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | Crystalline amrubicin hydrochloride |
WO2003035660A1 (fr) * | 2001-10-23 | 2003-05-01 | Sumitomo Chemical Company, Limited | Stabilisation d'hydrochlorure d'amrubicine |
Non-Patent Citations (1)
Title |
---|
See also references of EP1570849A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513519A (ja) * | 2005-05-11 | 2008-05-01 | シコール インコーポレイティド | 安定した凍結乾燥されたアントラサイクリングリコシド |
JP2009501708A (ja) * | 2005-07-14 | 2009-01-22 | インデナ・ソチエタ・ペル・アチオニ | チョウセンアザミ抽出物、その使用及びそれを含む配合物 |
WO2010137131A1 (ja) | 2009-05-27 | 2010-12-02 | 大日本住友製薬株式会社 | アンスラサイクリン系化合物の安定な凍結乾燥製剤 |
JP5389910B2 (ja) * | 2009-05-27 | 2014-01-15 | 大日本住友製薬株式会社 | アンスラサイクリン系化合物の安定な凍結乾燥製剤 |
US8785406B2 (en) | 2009-05-27 | 2014-07-22 | Dainippon Sumitomo Pharma Co., Ltd. | Stabilized and lyophilized formulation of anthracycline compounds |
Also Published As
Publication number | Publication date |
---|---|
JP4594736B2 (ja) | 2010-12-08 |
CA2509449A1 (en) | 2004-06-17 |
CN1741804A (zh) | 2006-03-01 |
US8445653B2 (en) | 2013-05-21 |
TWI311484B (ja) | 2009-07-01 |
TW200507859A (en) | 2005-03-01 |
CA2509449C (en) | 2012-01-31 |
EP1570849A1 (en) | 2005-09-07 |
CN101926780A (zh) | 2010-12-29 |
US20060003949A1 (en) | 2006-01-05 |
AU2003284478A1 (en) | 2004-06-23 |
EP1570849A4 (en) | 2010-07-07 |
CN101926780B (zh) | 2013-11-13 |
US20110021452A1 (en) | 2011-01-27 |
KR20050086863A (ko) | 2005-08-30 |
JPWO2004050098A1 (ja) | 2006-03-30 |
KR101059715B1 (ko) | 2011-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20040085196A (ko) | 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법 | |
JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
CN110876259B (zh) | 注射用组合物 | |
KR102459213B1 (ko) | 카르글룸산을 함유하는 약제학적 비경구 제형 | |
EP3008064B1 (en) | Stable pemetrexed arginine salt and compositions comprising it | |
US20110021452A1 (en) | Lyophilized preparation of stabilized anthracycline compounds | |
KR20180023914A (ko) | 안정된 경구 투여용 의약 조성물 | |
JP2603480B2 (ja) | 安定化されたアンスラサイクリン系製剤 | |
CN108697726B (zh) | 液态药物制剂 | |
JP2023026562A (ja) | シクロデキストリン及びブスルファンを含有する組成物 | |
US20230330079A1 (en) | Orally-disintegrating film comprising naratriptan | |
US20060063833A1 (en) | Ready-to-use oxaliplatin solutions | |
US20060089328A1 (en) | Ready-to-use gemcitabine solutions | |
PT727983E (pt) | Processo para a preparacao de um clodronato | |
JP5389910B2 (ja) | アンスラサイクリン系化合物の安定な凍結乾燥製剤 | |
KR101487953B1 (ko) | 유기용매 무함유 젬시타빈 수용액 조성물 | |
KR20030009426A (ko) | 캄프토테신 유도체 및 pH 조정물질을 함유하는 의약조성물 | |
US20060089329A1 (en) | Ready-to-use gemcitabine solution concentrates | |
WO2004000323A1 (ja) | セフェム化合物の注射用医薬組成物 | |
US20060063720A1 (en) | Oxaliplatin solution concentrate | |
WO2020055360A2 (en) | The parenteral composition comprising carfilzomib | |
TW200403064A (en) | Pharmaceutical composition for injection of cefem compound | |
TW201302755A (zh) | 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2509449 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006003949 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10536397 Country of ref document: US Ref document number: 2004556847 Country of ref document: JP Ref document number: 1020057009501 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775944 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A9192X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057009501 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775944 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10536397 Country of ref document: US |